Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-09

Clinical Trial Update: Phase III Study of ASP2151 in Herpes Simplex Patients [Phase 3]

View source ↗

Summary

Phase III trial of ASP2151 for herpes simplex infection has completed, with results posted on 2024-10-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASP2151

Snippet

Sponsor: Maruho Co., Ltd. | Conditions: Herpes Simplex | Phase 3 | Status: COMPLETED | Results posted: 2024-10-09